EMV Capital plc
("EMV Capital" or the "Company")
Director/PDMR Shareholding
EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment group, announces that on 2 October 2024, Dr Jonathan Robinson (Senior Independent Director) purchased 25,000 ordinary shares in the capital of EMV Capital plc ("Ordinary Shares") through his Self-Invested Personal Pension.
Following such purchase, Dr Robinson is interested in 199,253 Ordinary Shares, representing 0.82 per cent. of the entire issued share capital of the Company.
The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a) | Name | Dr Jonathan Robinson | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Director | ||||
| b)
| Initial notification /Amendment | Initial Notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | EMV Capital plc | ||||
| b) | LEI | 213800N5WD46G1Y7I458 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument Identification code | EMVC 5p Ordinary Shares
GB00BN4R5Q82 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares into SIPP | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information - Aggregated volume
- Price
|
| ||||
| e)
| Date of the transaction | 2 October 2024 | ||||
| f)
| Place of the transaction | UK AIM | ||||
# # #
| For more information, please contact: | |
| EMV Capital plc | via Rosewood |
| Ilian Iliev, CEO | |
|
|
|
| Panmure Liberum (UK) Limited (NOMAD and Broker) | +44 (0)20 7886 2500 |
| Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance) | |
| Rupert Dearden (Corporate Broking) | |
|
| |
| Rosewood (Financial PR) | +44 (0)20 7653 8702 |
| John West / Llewellyn Angus / Lily Pearce | |
About EMV Capital plc (EMVC)
EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.
With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
· capital-efficient investments through Group balance sheet;
· fund management of the Evergreen EIS and Martlet Capital Funds;
· syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
